ロード中...
2389. Effect of Rezafungin on QT Interval in Healthy Subjects
BACKGROUND: Rezafungin (RZF), a novel, once-weekly echinocandin for treatment and prophylaxis of invasive fungal infections, successfully met safety and efficacy endpoints in Phase 2 and is advancing to Phase 3 studies. RZF is the first echinocandin to undergo a definitive QT evaluation. METHODS: Th...
保存先:
| 出版年: | Open Forum Infect Dis |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255498/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.2042 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|